# A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL

> **NCT04361279** · PHASE3 · COMPLETED · sponsor: **Shanghai Institute Of Biological Products** · enrollment: 421 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** SIBP-02
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04361279
- **Lead sponsor:** Shanghai Institute Of Biological Products
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-25
- **Primary completion:** 2022-05-20
- **Final completion:** 2022-05-20
- **Target enrollment:** 421 (ACTUAL)
- **Last updated:** 2023-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04361279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04361279, "A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04361279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*